Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1105

Sort by

Sort Order Select

Journal Articles

Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies

Andrew W. Roberts, Freda K. Stevenson

Blood (2021) 138 (13): 1089.

https://doi.org/10.1182/blood.2021012674

Published: 2021

Journal Articles

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Deborah M. Stephens, John C. Byrd

Blood (2021) 138 (13): 1099–1109.

https://doi.org/10.1182/blood.2020006783

Published: 2021

Journal Articles

Myocarditis, kidney injury, and hypereosinophilia: FIP1L1-PDGFRA -positive myeloid/lymphoid neoplasm with eosinophilia

Sarah E. Reid, Shyam A. Patel

Blood (2021) 138 (12): 1086.

https://doi.org/10.1182/blood.2021011930

Published: 2021

Journal Articles

Myeloid/lymphoid neoplasm with FGFR1 rearrangement

Sharon Koorse Germans, Mingyi Chen

Blood (2021) 138 (10): 912.

https://doi.org/10.1182/blood.2021012168

Published: 2021

Journal Articles

BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells

Kimihito C. Kawabata, Hongliang Zong, Cem Meydan, Sarah Wyman, Bas J. Wouters, Mayumi Sugita, Srinjoy Goswami, Michael Albert, Winnie Yip, Gail J. Roboz, Zhengming Chen, Ruud Delwel, Martin Carroll, Christopher E. Mason, Ari Melnick, Monica L. Guzman

Blood (2021) 137 (6): 812–825.

https://doi.org/10.1182/blood.2019001745

Published: 2021

Includes: Supplemental data

Journal Articles

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

Bjoern Chapuy, Chip Stewart, Andrew J. Dunford, Jaegil Kim, Kirsty Wienand, Atanas Kamburov, Gabriel K. Griffin, Pei-Hsuan Chen, Ana Lako, Robert A. Redd, Claire M. Cote, Matthew D. Ducar, Aaron R. Thorner, Scott J. Rodig, Gad Getz, Margaret A. Shipp

Blood (2019) 134 (26): 2369–2382.

https://doi.org/10.1182/blood.2019002067

Published: 2019

Includes: Supplemental data

Journal Articles

Targeting the Activating Mutations of NOTCH1 in T-Cell Lymphoblastic Leukemia with a New SERCA Inhibitor CAD204520

Matteo Marchesini, PhD, Andrea Gherli, Anna Montanaro, Samuel Kitara, Claudia Sorrentino, Luca Pagliaro, Anne-Marie Lund Winter, Chiara Rompietti, Donatella Stilli, Federica Rizzi, Kimberly Stegmaier, MD, Paolo Sportoletti, William Dalby-Brown, Giovanni Roti

Blood (2019) 134 (Supplement_1): 407.

https://doi.org/10.1182/blood-2019-125616

Published: 2019

Journal Articles

Disparities and Their Impact on the Adoption of Health Information Technology (HIT) in Minority Cancer Patients and Caregivers

Sikander Ailawadhi, MD, Meghna Ailawadhi, MD, Srilekha Bodepudi, Mays F Abdulazeez, BMSC, Zan Tahir Shareef, Ashna Grover, Maria J Fernandez, Winston Tan, MD, Victoria R. Alegria, Taimur Sher, MD, Vivek Roy, MD, Rami Manochakian, MD, Aneel Paulus, MD, Asher A. Chanan-Khan, MD

Blood (2019) 134 (Supplement_1): 411.

https://doi.org/10.1182/blood-2019-125722

Published: 2019

Journal Articles

Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)

Blood (2019) 134 (Supplement_1): 516.

https://doi.org/10.1182/blood-2019-129520

Published: 2019

Journal Articles

Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial)

David Gottlieb, MBBS, MD FRACP, FRCPA, Wei Jiang, MBBS, BSc, BA, Selmir Avdic, PhD, Leighton Clancy, BSc PhD, Gaurav Sutrave, MBBS, Caroline M Bateman, PhDMBBS,FRACP,FRCPath,MRCP, Elissa Atkins, RN, Adrian Gabriel Selim, MBBS, Vicki Antonenas, BSc, David Collins, RN BSc (HONS) MN MapptMgt, Janine Street, BSc MSc (Hons), Renee Simms, BSc, Peter J. Shaw, MA,FRACP, David Ritchie, MD PhD, Emily Blyth, B. MDHons), FRACP, FRCPA, PhD

Blood (2019) 134 (Supplement_1): 251.

https://doi.org/10.1182/blood-2019-125166

Published: 2019

Journal Articles

A Multicenter Study of Romiplostim to Treat Chemotherapy-Induced Thrombocytopenia in Solid Tumors and Lymphoid Malignancies

Hanny Al-Samkari, MD, Aric D Parnes, MD, Katayoon Goodarzi, MD, James I Weitzman, MD, Jean M. Connors, MD, David J. Kuter

Blood (2019) 134 (Supplement_1): 389.

https://doi.org/10.1182/blood-2019-123864

Published: 2019

Journal Articles

A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas

William Pearse, MD, Barbara Pro, MD, Leo I. Gordon, MD, Reem Karmali, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Amir Behdad, MD, Andreas Klein, MD, Adam M. Petrich, MD, Borko Jovanovic, PhD, Sonali M. Smith, MD, Andrew G Evans, MD PhD

Blood (2019) 134 (Supplement_1): 351.

https://doi.org/10.1182/blood-2019-127390

Published: 2019

Journal Articles

Factors Associated with Subsequent Cancers in Patients with Moderate or Severe Chronic Graft-Versus-Host Disease after Transplant for Hematologic Malignancy

Dana Schaar, Filip Pirsl, Seth M. Steinberg, PhD, Laura Parsons-Wandell, Michael Emanuel, Shaneil Flucker, Jeannette Nashed, Claire Ruben, Lauren M. Curtis, MD, Edward W Cowen, MD, Jacqueline Mays, PhD DDS, Pashna N. Munshi, MD, Annie Im, MD, Ann Berger, MD, Galen O Joe, MD, Manuel B Datiles, III, MD, Steven Z. Pavletic, MD MS

Blood (2019) 134 (Supplement_1): 4558.

https://doi.org/10.1182/blood-2019-124020

Published: 2019

Journal Articles

Therapy Related Myeloid Neoplasms- Clinical, Pathologic and Genetic Characteristics - a Single Center Experience

Dina Sameh Soliman, MD MB, MMSc, Ahmed Al-Sabbagh, MD, Shehab Fareed Mohamed, MD, Susanna Jane Akiki, PhD, Halima El-Omri, MD, Firyal Ibrahim, MD, Mohamed A Yassin, MBBS, MSc, Prem Chandra, PhD

Blood (2019) 134 (Supplement_1): 5169.

https://doi.org/10.1182/blood-2019-124951

Published: 2019

Journal Articles

Low Lymphocyte Count at Day 30 after Single Cord Blood Transplantation Had Negative Impact on Survival, Because of Higher NRM Rate

Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Daisuke Kaji, MD, Yuki Taya, MD PhD, Shinsuke Takagi, Hisashi Yamamoto, MD PhD, Go Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Atsushi Wake, MD PhD, Akiko Yoneyama, MD PhD, Shigeyoshi Makino, MD PhD, Naoyuki Uchida, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2019) 134 (Supplement_1): 4482.

https://doi.org/10.1182/blood-2019-130662

Published: 2019

Journal Articles

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy

Merav Bar, MD, Julia Ruark, MD MPH, Erin Mullane, DNP, Nancy Cleary, BSc, Ana Cordeiro, MD, Evandro D. Bezerra, MD, Jenna M. Voutsinas, MPH, Bronwen E. Shaw, MD PhD, Qian Vicky Wu, PhD, Kathryn E Flynn, PhD, Stephanie J. Lee, MD MPH, Cameron J. Turtle, MBBS, PhD, David G. Maloney, MD PhD, Jesse Fann

Blood (2019) 134 (Supplement_1): 4453.

https://doi.org/10.1182/blood-2019-122755

Published: 2019

Journal Articles

Rive-CLL: Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

John McKay, DO, Taha Al-Juhaishi, MD, Lai Guanhua, MD PhD, Maciej Kmieciak, PhD, Roy Sabo, PhD, Ariel Sindel, DO, Victor Yazbeck, MD

Blood (2019) 134 (Supplement_1): 5482.

https://doi.org/10.1182/blood-2019-126335

Published: 2019

Journal Articles

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO)

Anna Vanazzi, MD, Safaa Ramadan, PhD MD, Francesca De Lorenzi, MD, Paola Arena, MD, Enrico Derenzini, MD PhD, Mario Rietjens, Anna Rotili, MD, Antuono Latronico, MD, Laura Travaini, MD, Emanuela Omodeo Sale', Daniela Malengo, Marianna Gerardi, Stefano Fiori, MD, Valentina Tabanelli, MD, Stefano A Pileri, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 5283.

https://doi.org/10.1182/blood-2019-125239

Published: 2019

Journal Articles

Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR

Zaid Abdel Rahman, MD, Nicole Gannon, PA-C, Megan Melody, MD, Paul Muniz, RN, Ernesto Ayala, MD, Vivek Roy, MD, Lisa Brumble, Sikander Ailawadhi, MD, Taimur Sher, MD, James M. Foran, MD, Hemant S. Murthy, MD, Han W. Tun, MD, Candido E. Rivera, MD, Asher A. Chanan-Khan, MD, Abba C. Zubair, MD PhD, Mohamed A Kharfan-Dabaja, MDMBA

Blood (2019) 134 (Supplement_1): 5610.

https://doi.org/10.1182/blood-2019-122067

Published: 2019

Journal Articles

Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCM1-FGFR1 Fusion: Data from an Expanded Access Program

Monica Kasbekar, Valentina Nardi, MD, Paola Dal Cin, Andrew M. Brunner, MD, Yi-Bin Chen, Christine Connolly, Amir T. Fathi, MD, Julia Foster, ANP, Molly Macrae, Steven L McAfee, MD, Kristin McGregor, Rupa Narayan, Aura Y. Ramos, Tina T. Som, RN, Megan Vartanian, RN, Robb S Friedman, MD, Karim Benhadji, MD MSC, Gabriela S. Hobbs, MD

Blood (2019) 134 (Supplement_1): 5371.

https://doi.org/10.1182/blood-2019-124100

Published: 2019

NARROW

Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Myocarditis, kidney injury, and hypereosinophilia: FIP1L1-PDGFRA -positive myeloid/lymphoid neoplasm with eosinophilia

Myeloid/lymphoid neoplasm with FGFR1 rearrangement

BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells

Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade

Targeting the Activating Mutations of NOTCH1 in T-Cell Lymphoblastic Leukemia with a New SERCA Inhibitor CAD204520

Disparities and Their Impact on the Adoption of Health Information Technology (HIT) in Minority Cancer Patients and Caregivers

Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)

Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial)

A Multicenter Study of Romiplostim to Treat Chemotherapy-Induced Thrombocytopenia in Solid Tumors and Lymphoid Malignancies

A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas

Factors Associated with Subsequent Cancers in Patients with Moderate or Severe Chronic Graft-Versus-Host Disease after Transplant for Hematologic Malignancy

Therapy Related Myeloid Neoplasms- Clinical, Pathologic and Genetic Characteristics - a Single Center Experience

Low Lymphocyte Count at Day 30 after Single Cord Blood Transplantation Had Negative Impact on Survival, Because of Higher NRM Rate

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy

Rive-CLL: Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO)

Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR

Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCM1-FGFR1 Fusion: Data from an Expanded Access Program

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only